Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 234Neoplasms 206Carcinoma, Non-Small-Cell Lung 100Colorectal Neoplasms 98Prostatic Neoplasms 93Lung Neoplasms 78Multiple Myeloma 53Melanoma 51Pancreatic Neoplasms 50Head and Neck Neoplasms 49Neoplasm Metastasis 47Leukemia, Myeloid, Acute 43Carcinoma, Hepatocellular 43Ovarian Neoplasms 39Brain Neoplasms 39Squamous Cell Carcinoma of Head and Neck 36Recurrence 35Glioblastoma 33Uterine Cervical Neoplasms 32Sarcoma 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Glioma 29Lymphoma, Non-Hodgkin 28Lymphoma 27Colonic Neoplasms 27Stomach Neoplasms 26Carcinoma, Renal Cell 26Lymphoma, Follicular 25Esophageal Neoplasms 24Rectal Neoplasms 23

Interventions

rasburicase 1Uric Acid 1Urate Oxidase 1Pegloticase 1Oxidoreductases 1Carbamates 1Amides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Tumor Lysis Syndrome × 90 days × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡